The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of concurrent nab-paclitaxel, carboplatin, and IMRT for locally advanced squamous cancer of the head and neck (LASCCHN).
Roy B. Tishler
Research Funding - Celgene
Jochen H. Lorch
No relevant relationships to disclose
David J Sher
No relevant relationships to disclose
John Ross Clark
No relevant relationships to disclose
Annie W Chan
No relevant relationships to disclose
Margaret Suda
No relevant relationships to disclose
Tracy A. Balboni
No relevant relationships to disclose
Paul M. Busse
No relevant relationships to disclose
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Sanofi
Lori J. Wirth
No relevant relationships to disclose